
Patton has strong feelings about treating scabies without proof—until penile papules enter the chat. Plus, the Derms rethink familiar prescriptions during cancer immunotherapy and referee a topical showdown: compounded tofa, mometasone, and Eucrisa.
Derms on Drugs is where cutting-edge dermatology meets mediocre comedy. Each week three dermatologists – Matt Zirwas, Laura Ferris and Tim Patton – discuss, debate, and dissect the hottest topics in dermatology. It's everything you need to know to be on the cutting-edge of dermatology and it’ll be…

Patton has strong feelings about treating scabies without proof—until penile papules enter the chat. Plus, the Derms rethink familiar prescriptions during cancer immunotherapy and referee a topical showdown: compounded tofa, mometasone, and Eucrisa.

A stubborn ulcer, a murky diagnosis, and the temptation to throw every drug at it. Dr. Ben Kaffenberger helps the Derms untangle pyoderma gangrenosum—from diagnostic traps to treatment choices and why a closed wound isn’t always a closed case.

Dr. Jason Hawkes makes the case for putting speed first when choosing an advanced treatment for CSU. Remibrutinib works fast—but can he convince the Derms that fast is reason enough to put it first?

The Derms stay in Vienna for round two of EADV, where zombie-cell cream meets new pathways in HS and AD—plus a JAK surprise in PPP and reassuring pregnancy data.

EADV serves up better croissants—and a packed menu of new mechanisms. The Derms dig into injectable RNA for BCC, a possible anti-scarring angle in HS, a TYK2 showdown, and an alopecia treatment that may keep working after treatment ends.

Dr. Jason Hawkes makes the case for putting speed first when choosing an advanced treatment for CSU. Remibrutinib works fast—but can he convince the Derms that fast is reason enough to put it first?

The Derms size up high-dose vitamin D, a head-to-head lichen planus trial, and whether contact dermatitis testing is overcalling the culprit.

The Derms question treatment monogamy: a personalized melanoma vaccine joins forces with immunotherapy, while dual therapy takes on refractory HS and AD.

In Utah, AI is getting its hands on the prescription pad—starting with topical acne treatment. The Derms grill Nolla’s CEO on the big questions: Who catches the misses, and is this better access or the beginning of the robot takeover?

Dr. Steve Daveluy makes the case that Cosentyx is the “just right” first biologic for HS—but not every Derm is ready to move past TNFs. Durability, infection risk, IBD, and insurance all enter the argument.

Exosomes may be real science, but the marketing has sprinted miles ahead of the data. The Derms dig into their promise for burns and epidermolysis bullosa—and why that pricey cosmetic vial may not contain what it claims.

Three papers, three practical questions: Who really needs antibiotics before derm surgery? What comes after an AD drug fails? And does taking oral minoxidil in the morning actually grow more hair—or just raise more eyebrows?
We use cookies to run this site. Analytics cookies, which show us how it's used, stay off unless you accept them. Change your mind any time with the cookie button at the bottom right. How we use cookies